Tuning Reactivity of Platinum(II) Complexes

Altona J. H. van Boom, G. A. van der Marel, C. A. G. Haasnoot, J. Reedijk, J. Am.
Chem., Soc. 1984, 106, 1528.
47 P. J. Morin, Drug Resist Update, 2003, 6, 169.
48 (a) Z. H. Siddik, Oncogene, 2003, 22, 7265; (b) D. J. Stewart, Crit. Rev. Oncol.
Hematol., 2007, 63, 12.
49 J. Reedijk, Chem. Rev., 1999, 99, 2499-2510.
50 (a) S. S. G. E. van Boom and J. Reedijk, J. Chem. Soc., Chem. Commun. 1993, 18,
1397–1398; (b) K.J. Barnham, Z. Guo, P. J. Sadler, J. Chem. Soc., Dalton Trans. 1996,
13, 2867–2876; (c) J. M. Teuben, S. S.G. E. van Boom, J. Reedijk, J. Chem. Soc.,
Dalton Trans. 1997, 21, 3979–3980 (d) Y. Chen, Z. Guo, P. del S. Murdoch, E. Zang,
P. J. Sadler, J. Chem. Soc, Dalton Trans. 1998, 9, 1503–1508.
51 D. Du Plessi-Stoman, MSC. Thesis, Nelson Mandela Metropolitan University, South
Africa, 2006, p 15.
52 C. H. Versantvoort, H. J. Broxterman, T. R. Badrij, J. Scheper and P. R. Twentyman,
J. Cancer, 1995, 72, 82.
53 A. Pasini and C. Fiore, Inorg. Chim. Acta., 1999, 285, 249.
54 (a) N. J. Wheate, S. Walker, G. E. Craig and R. Oun , Dalton trans., 2010, 39, 8113-
8127; (b) J. Reedijk, Chem. Rev., 1999, 99, 2499.
55 E. Cvitkovic, Cancer Treatment Reviews, 1998, 24, 265-281.
56 C. Molenaar, J.-M. Teuben, R. J. Heetebrij, H. J. Tanke and J. Reedijk, J. Biol. Inorg.
Chem. 2000, 5, 655–665.
57 G. Samimi, K. Katano, A. K. Holzer et al., Mol. Pharmacol., 2004, 66, 25–32.
58 S. Neidle, I. M. Ismail and P. J.Sadler, J. Inorg. Biochem,. 1980, 13, 205–212.
59 U. FREY, J. D. RANFORD AND P. J. SADLER, INORG. CHEM., 1993, 32, 1333–1340.
60. (a) T. Bolelikas and M. Vougiouka, Oncol. Reports, 2003, 10, 1663; (b) J. M.
Woynarowski, S. Faivre, M. C. S. Herzig, B. Arnett, W. G. Chapman, A. V. Trevino, E.
Raymond, S. G. Chaney, A. Vaisman, M. Varchenko, P. E. Juniewicz, Mol.
Pharmacol. 2000, 58, 920.
61 (a) J. Holford, F. Raymond, B. A. Murrer, K. Grimaldi, J. A. Hartley, M. Abrams and
L. R. Kelland, Anticancer Drug Des., 1998, 13, 1; (b) M. Hay, Curr. Opin. Oncol.,
23